Psilocybin Trial for Anorexia Nervosa in Adolescents: A New Frontier

Psilocybin's Potential in Treating Anorexia Nervosa

A groundbreaking clinical trial is exploring the use of psilocybin to treat anorexia nervosa (AN) in adolescents and young adults. This study, known as the psiAN study, represents a significant step in addressing a psychiatric disorder that has high morbidity and relapse rates. Anorexia nervosa often emerges during adolescence, and current treatments have limited success. By focusing on this demographic, the trial aims to uncover new therapeutic avenues.

Study Design and Mechanistic Insights

The psiAN study is a Phase IIa, open-label, randomized controlled trial (ClinicalTrials.gov Identifier: NCT07169747) that includes participants aged 16-35 years with DSM-5 diagnosed anorexia nervosa and a history of relapse. Participants receive either two doses of psilocybin (25 mg) with manualized psychological support plus treatment as usual (TAU), or TAU alone. The trial incorporates neurobiological measures, such as functional magnetic resonance imaging (fMRI) and peripheral brain-derived neurotrophic factor, to explore psilocybin's mechanistic effects on brain function and structure.

Policy and Research Implications

This trial could have significant implications for both policy and future research. By demonstrating the safety and efficacy of psilocybin in a vulnerable population, the study may influence regulatory perspectives on psychedelic therapies, potentially leading to broader acceptance and integration into psychiatric care. The inclusion of neurobiological measures like fMRI could also inform future studies by providing insights into how psilocybin affects brain connectivity and function.

Risks and Unknowns

Despite the potential benefits, there are inherent risks and unknowns associated with the use of psilocybin in adolescents. The trial's design, which includes rigorous safety monitoring and adherence to Good Clinical Practice (GCP) standards, aims to mitigate these risks. However, the long-term effects of psilocybin, particularly in a developing brain, remain uncertain. The study's phased inclusion of adolescents, following safety reviews of adult data, reflects a cautious approach to these uncertainties.

Looking Forward: The Future of Psychedelic Research

The psiAN study could pave the way for new interventions in treating anorexia nervosa and potentially other psychiatric disorders. As the trial progresses, its findings may provide valuable data on the safety and efficacy of psilocybin, informing both clinical practice and future research. The exploration of psilocybin's mechanistic effects could also contribute to a broader understanding of its role in psychiatric care, potentially leading to novel therapeutic strategies.